Dr. Robert F. Tassan, MD

Media Releases

Get to know Hematologist-Oncologist Dr. Robert F. Tassan, who serves patients throughout the State of New Jersey.

A highly trained hematologist-oncologist, Dr. Tassan has been treating patients in Bergen County for more than 8 years. He is currently affiliated with Regional Cancer Care Associates, seeing patients at their offices in Franklin Lakes and Westwood, New Jersey.

With over 20 locations throughout New Jersey, Connecticut, Maryland, and the Washington, DC area, the cancer and blood disorder specialists at Regional Cancer Care Associates offer world-class care close to home, so that patients can focus on the most important thing in the world – their health.

Pertaining to his educational pursuits, Dr. Tassan graduated with his medical degree from the UMDNJ Robert Wood Johnson Medical School. He then went on to further his training by completing a residency in internal medicine and a fellowship in hematology/medical oncology at the UMDNJ Robert Wood Johnson University Hospital. He also holds a Bachelor of Science degree from Manhattan College.

As a testament of his continued education, the doctor is board-certified in hematology, medical oncology, and internal medicine by the American Board of Internal Medicine (ABIM). The ABIM is a physician-led, non-profit, independent evaluation organization driven by doctors who want to achieve higher standards for better care in a rapidly changing world.

In his professional experience, he has admitting privileges at HMH Hackensack University Medical Center and Pascack Valley Medical Center, and serves as an associate of the Advisory Board for Physician Leadership Development at The Valley Hospital.

Hematology is the branch of medicine concerned with the study of the cause, prognosis, treatment, and prevention of diseases related to blood. Oncology is a branch of medicine that deals with the prevention, diagnosis, and treatment of cancer. A hematologist-oncologist is a physician who specializes in the diagnosis, treatment, or prevention of cancer, malignant blood diseases such as leukemia, lymphoma, and multiple myeloma, and blood disorders such as iron-deficiency anemia, clotting abnormalities, hemophilia, and sickle-cell disease.

Among his most notable achievements, Dr. Tassan has been the recipient of the Melvyn H. Motolinsky Outstanding Fellow Award.

Recommended Articles

• Living with Lymphoma Day by Day

  A majority of individuals diagnosed with lymphoma find that they have to make a great deal of adjustments to their lives. There are several physical, emotional, social, and everyday obstacles from diagnosis to remission.Living with lymphoma can be different for every individual, which is why it is...

• Promising Results for Hodgkin Patients Using This Therapy

  Researcher Dr. Bradford S. Hoppe and his colleagues at the University of Florida College of Medicine have recently found that the addition of proton therapy to first-line chemotherapy regimens may improve outcomes for patients with Hodgkin lymphoma.Lymphoma is classically treated with both...

• Genetic Advancements in Lymphoma Treatment

  Cancers are a huge focus for research. Millions of dollars every year are funneled into funding research that could improve treatment methods or find cures for cancer, including blood cancers. Diffuse large B cell lymphoma (DLBCL) is the most common form of non-Hodgkin’s lymphoma (NHL) accounting...

• Breaking News on the Treatment of Follicular Lymphoma

  Reuters, the international news agency out of London, has announced that the FDA has given a new drug “accelerated approval,” for the treatment of follicular lymphoma.The drug, Aliqopa (copanlisib), showed complete or partial shrinkage of tumors in 59% of study participants during drug studies,...

• AstraZeneca Gains United States Approval for Lymphoma Drug

  Some forms of lymphoma are rarer than others. Most people can recognize Hodgkin lymphoma, but mantle cell lymphoma will strike them as a surprise.Because it is so rare, there are not as many drugs specific to this form of cancer. One has recently been approved in the United States, by the Food and...

• Bringing Chronic Lymphocytic Leukemia Patients and Their Doctors Together via Survey

  While patients may entirely admire and respect their doctors, sometimes they simply do not agree with the course of action they are proposing. While this may not be a big deal for a visit about a cold or something minimal, it can be life-altering for those with chronic conditions. That is why a...